Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05285566
PHASE4

Pain Control for Undergoing Costal Cartilage Harvesting

Sponsor: Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.

Official title: A Phase IV Randomized, Single-Blind Trial of Liposomal Bupivacaine (Exparel®) for Pain Control in Costal Cartilage Harvest

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2022-05-04

Completion Date

2026-09

Last Updated

2025-09-12

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Exparel

106mg (8 mL) subcutaneous injection injected after costal cartilage harvest

DRUG

Xylocaine

8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site

Locations (1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States